Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Active not recruiting × vandetanib × Clear all

Phase

Phase 3 1 Phase 2 1

Status

Completed 5 Withdrawn 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Medullary 1

Interventions

Carboplatin 96 Cisplatin 87 Paclitaxel 75 pembrolizumab 61 Gemcitabine 50 Cyclophosphamide 47 Capecitabine 44 durvalumab 43 Pemetrexed 41 Dexamethasone 40 Doxorubicin 39 Radiotherapy 37 Docetaxel 37 Nivolumab 35 Lenalidomide 34 Bevacizumab 32 Specimen Handling 31 Oxaliplatin 31 Rituximab 30 Etoposide 30 Vincristine 29 Magnetic Resonance Spectroscopy 29 Fluorouracil 29 atezolizumab 26 Radiation 24 Prednisone 24 Leucovorin 24 Bortezomib 24 130-nm albumin-bound paclitaxel 22 Letrozole 20

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04211337 2025-04-20

LIBRETTO-531

Eli Lilly and Company

Phase 3 Active not recruiting

291 enrolled 16 charts 1 FDA

Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡